

Kluwer Patent Blog

Poland: Bolar Exemption, Supreme Court 23 October 2013

Krystyna Szczepanowska-Kozłowska (Allen & Overy) · Thursday, May 8th, 2014

The Bolar exemption must be interpreted narrowly in order not to affect the patent holder's exclusive rights. The privilege of the generic drug manufacturers who are allowed to conduct clinical trials in order to seek regulatory approval for their therapeutic products based on patented inventions does not apply to their third-party suppliers. Thus, manufacturing of patented pharmaceutical ingredients and offering them to generic drug companies constitutes patent infringement.

The [full summary](#) of this case has been published on [Kluwer IP Law](#).

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).



Want to improve your IP strategy?

- Manual of Industrial Property
- IP Analytics
- Visser – Annotated European Patent Convention

230+ jurisdictions
36,000+ cases
100+ books
600+ IP law professionals as authors

Request a free demo now
KluwerIPLaw.com

Wolters Kluwer

This entry was posted on Thursday, May 8th, 2014 at 8:00 am and is filed under [\(Indirect\) infringement](#), [Case Law](#), [Poland](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.

